215 related articles for article (PubMed ID: 31808881)
1. Pediatric-inspired protocols in adult acute lymphoblastic leukemia: are the results bearing fruit?
Muffly L; Curran E
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):17-23. PubMed ID: 31808881
[TBL] [Abstract][Full Text] [Related]
2. The impact of total body irradiation-based regimens on outcomes in children and young adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation.
Friend BD; Bailey-Olson M; Melton A; Shimano KA; Kharbanda S; Higham C; Winestone LE; Huang J; Stieglitz E; Dvorak CC
Pediatr Blood Cancer; 2020 Feb; 67(2):e28079. PubMed ID: 31724815
[TBL] [Abstract][Full Text] [Related]
3. A Single Institution's Experience with Cytogenetic and MRD Outcomes in Pediatric Acute Lymphoblastic Leukemia.
Amjad A; Wali RM; Anjum S; Mansoor R
J Coll Physicians Surg Pak; 2019 Jun; 29(6):549-552. PubMed ID: 31133155
[TBL] [Abstract][Full Text] [Related]
4. Cross-sectional physician survey on the use of minimal residual disease testing in the management of pediatric and adult patients with acute lymphoblastic leukemia.
Kim C; Delaney K; McNamara M; Chia V; Romanov V
Hematology; 2019 Dec; 24(1):70-78. PubMed ID: 30129384
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of allogeneic transplantation in first or later minimal residual disease - negative remission following adult-inspired therapy for acute lymphoblastic leukemia.
Cassaday RD; Alan Potts D; Stevenson PA; Bar M; Georges GE; Shustov AR; Sorror ML; Wood BL; Delaney C; Doney KC; Storb RF; Sandmaier BM
Leuk Lymphoma; 2016 Sep; 57(9):2109-18. PubMed ID: 27002921
[TBL] [Abstract][Full Text] [Related]
6. [Acute lymphoblastic leukemia in adolescents and young adults: from the viewpoint of pediatricians].
Koh K
Rinsho Ketsueki; 2017; 58(8):1024-1030. PubMed ID: 28883265
[TBL] [Abstract][Full Text] [Related]
7. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen.
Rytting ME; Jabbour EJ; Jorgensen JL; Ravandi F; Franklin AR; Kadia TM; Pemmaraju N; Daver NG; Ferrajoli A; Garcia-Manero G; Konopleva MY; Borthakur G; Garris R; Wang S; Pierce S; Schroeder K; Kornblau SM; Thomas DA; Cortes JE; O'Brien SM; Kantarjian HM
Am J Hematol; 2016 Aug; 91(8):819-23. PubMed ID: 27178680
[TBL] [Abstract][Full Text] [Related]
8. [The treatment development for T cell acute lymphoblastic leukemia in children, adolescents, and young adults].
Sato A
Rinsho Ketsueki; 2022; 63(9):1325-1334. PubMed ID: 36198559
[TBL] [Abstract][Full Text] [Related]
9. [Treatment strategy for acute lymphoblastic leukemia in adolescent and young adults].
Yamazaki E
Rinsho Ketsueki; 2022; 63(7):826-832. PubMed ID: 35922954
[TBL] [Abstract][Full Text] [Related]
10. Minimal Residual Disease Assessment and Risk-based Therapy in Acute Lymphoblastic Leukemia.
Bassan R; Intermesoli T; Scattolin A; Viero P; Maino E; Sancetta R; Carobolante F; Gianni F; Stefanoni P; Tosi M; Spinelli O; Rambaldi A
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S2-S9. PubMed ID: 28760298
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease.
Issa GC; Kantarjian HM; Yin CC; Qiao W; Ravandi F; Thomas D; Short NJ; Sasaki K; Garcia-Manero G; Kadia TM; Cortes JE; Daver N; Borthakur G; Jain N; Konopleva M; Khouri I; Kebriaei P; Champlin RE; Pierce S; O'Brien SM; Jabbour E
Cancer; 2017 Feb; 123(3):459-467. PubMed ID: 27696391
[TBL] [Abstract][Full Text] [Related]
12. Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Review.
Siegel SE; Stock W; Johnson RH; Advani A; Muffly L; Douer D; Reed D; Lewis M; Freyer DR; Shah B; Luger S; Hayes-Lattin B; Jaboin JJ; Coccia PF; DeAngelo DJ; Seibel N; Bleyer A
JAMA Oncol; 2018 May; 4(5):725-734. PubMed ID: 29450465
[TBL] [Abstract][Full Text] [Related]
13. Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT.
Pavlů J; Labopin M; Niittyvuopio R; Socié G; Yakoub-Agha I; Wu D; Remenyi P; Passweg J; Beelen DW; Aljurf M; Kröger N; Labussière-Wallet H; Perić Z; Giebel S; Nagler A; Mohty M
J Hematol Oncol; 2019 Oct; 12(1):108. PubMed ID: 31647022
[TBL] [Abstract][Full Text] [Related]
14. Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy.
Pui CH; Pei D; Raimondi SC; Coustan-Smith E; Jeha S; Cheng C; Bowman WP; Sandlund JT; Ribeiro RC; Rubnitz JE; Inaba H; Gruber TA; Leung WH; Yang JJ; Downing JR; Evans WE; Relling MV; Campana D
Leukemia; 2017 Feb; 31(2):333-339. PubMed ID: 27560110
[TBL] [Abstract][Full Text] [Related]
15. Clinical value of pre-transplant minimal residual disease in childhood lymphoblastic leukaemia: the results of the French minimal residual disease-guided protocol.
Gandemer V; Pochon C; Oger E; Dalle JH; Michel G; Schmitt C; de Berranger E; Galambrun C; Cavé H; Cayuela JM; Grardel N; Macintyre E; Margueritte G; Méchinaud F; Rorhlich P; Lutz P; Demeocq F; Schneider P; Plantaz D; Poirée M; Bordigoni P
Br J Haematol; 2014 May; 165(3):392-401. PubMed ID: 24479958
[TBL] [Abstract][Full Text] [Related]
16. Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD vs. pediatric-inspired regimens.
Siegel SE; Advani A; Seibel N; Muffly L; Stock W; Luger S; Shah B; DeAngelo DJ; Freyer DR; Douer D; Johnson RH; Hayes-Lattin B; Lewis M; Jaboin JJ; Coccia PF; Bleyer A
Am J Hematol; 2018 Oct; 93(10):1254-1266. PubMed ID: 30058716
[TBL] [Abstract][Full Text] [Related]
17. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
[TBL] [Abstract][Full Text] [Related]
18. Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
Yoon JH; Yhim HY; Kwak JY; Ahn JS; Yang DH; Lee JJ; Kim SJ; Kim JS; Park SJ; Choi CW; Eom HS; Park SK; Choi SY; Kim SH; Kim DW; Lee S
Ann Oncol; 2016 Jun; 27(6):1081-1088. PubMed ID: 26951627
[TBL] [Abstract][Full Text] [Related]
19. Impact of pretransplant minimal residual disease on the post-transplant outcome of pediatric acute lymphoblastic leukemia.
Umeda K; Hiramatsu H; Kawaguchi K; Iwai A; Mikami M; Nodomi S; Saida S; Heike T; Ohomori K; Adachi S
Pediatr Transplant; 2016 Aug; 20(5):692-6. PubMed ID: 27256540
[TBL] [Abstract][Full Text] [Related]
20. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.
Sramkova L; Muzikova K; Fronkova E; Krejci O; Sedlacek P; Formankova R; Mejstrikova E; Stary J; Trka J
Pediatr Blood Cancer; 2007 Jan; 48(1):93-100. PubMed ID: 16521130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
